Sus I, Hadadi L, Somkereki C, Dobreanu D
"George Emil Palade" University of Medicine, Pharmacy, Science and Technology, Tirgu Mures, Romania.
Emergency Institute for Cardiovascular Diseases and Transplantation - Tirgu Mures, Romania.
Acta Endocrinol (Buchar). 2021 Oct-Dec;17(4):543-547. doi: 10.4183/aeb.2021.543.
Platelet indices change in relation to cardiovascular risk factors, including type 2 diabetes mellitus (T2DM). An increase of platelet indices over time in patients undergoing percutaneous coronary intervention (PCI) could be a predictor of mortality.The objective of this study was to assess differences in platelet indices in patients with and without T2DM undergoing PCI, prior and more than one month after the procedure.
In this retrospective observational study, patients undergoing PCI were included. Data were extracted from PCI Registry of the Emergency Institute for Cardiovascular Diseases and Transplantation of Tirgu Mures, Romania.
Of the 718 patients included in the study, 222 (30.9%) had T2DM; 61% of patient underwent PCI for SCAD, the rest for NSTE-ACS or STEMI. Prior to PCI, MPV, PDW and P-LCR were not higher in T2DM patients irrespective of the indication for PCI. At a follow-up time of 69 (46-98) days, platelet indices were not different between TD2M+ and T2DM-, except from MPV (11.0 . 10.6, p=0.02) which were higher in TD2M patients with SCAD. Intraindividual variability of platelet indices was not different in diabetics, but MPV, PDW and platelet count decreased over time (3.5% and 8.4% respectively) in diabetics with STEMI (p=0.02).
Platelet indices were not higher in patients with T2DM undergoing PCI, but we observed an important variation in platelet indices in diabetics after STEMI related PCI.
血小板指标会随着心血管危险因素而变化,包括2型糖尿病(T2DM)。接受经皮冠状动脉介入治疗(PCI)的患者血小板指标随时间增加可能是死亡率的一个预测指标。本研究的目的是评估接受PCI的T2DM患者和非T2DM患者在手术前及术后一个多月时血小板指标的差异。
本回顾性观察研究纳入了接受PCI的患者。数据从罗马尼亚特尔古穆列什心血管疾病和移植急诊研究所的PCI登记处提取。
在纳入研究的718例患者中,222例(30.9%)患有T2DM;61%的患者因ST段抬高型急性冠状动脉综合征(SCAD)接受PCI,其余患者因非ST段抬高型急性冠状动脉综合征(NSTE-ACS)或ST段抬高型心肌梗死(STEMI)接受PCI。在PCI术前,无论PCI的适应证如何,T2DM患者的平均血小板体积(MPV)、血小板分布宽度(PDW)和血小板大细胞比率(P-LCR)均不更高。在69(46-98)天的随访期内,T2DM+组和T2DM-组之间的血小板指标没有差异,但SCAD的T2DM患者的MPV(11.0对10.6,p=0.02)更高。糖尿病患者血小板指标的个体内变异性没有差异,但STEMI糖尿病患者的MPV、PDW和血小板计数随时间下降(分别为3.5%和8.4%)(p=0.02)。
接受PCI的T2DM患者的血小板指标并不更高,但我们观察到STEMI相关PCI术后糖尿病患者的血小板指标有重要变化。